The majority of PDAC (~ 90%) and a high proportion (25–40%) of NSCLC harbor oncogenic activation of KRAS [28–31], which have been demonstrated to be necessary to both initiate and maintain tumorigenesis [32]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.